# Vivesto

Source: https://onco.cc/companies/vivesto/  
OnCo record `vivesto` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Vivesto is a Swedish company developing cancer medicines, listed in Stockholm. Its human medicine Cantrixil is being developed for blood cancer and has orphan drug status in the United States for acute myeloid leukaemia.

## Summary

Vivesto AB, based in Solna, Sweden, describes itself as a drug development company for hard-to-treat cancers; its shares trade on Nasdaq Stockholm under the ticker VIVE. Its portfolio is Cantrixil, being developed for blood cancers, and the veterinary oncology programme Paccal Vet (paclitaxel micellar), in a pilot trial in dogs with splenic haemangiosarcoma and a dose-finding study in cats. On 1 November 2026 the FDA granted orphan drug designation to Cantrixil for acute myeloid leukaemia; the company announced it on 3 November 2026 and said it is working towards a phase 1 study in AML. The FDA had designated Cantrixil for ovarian cancer in 2015.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Vivesto AB
- HQ: Solna
- Type: biotech
- Website: https://www.vivesto.com/en/
- Ticker: VIVE

## Notes

- Read on vivesto.com on 4 November 2026.

## Sources

- Official website: https://www.vivesto.com/en/
- Orphan drug designation for Cantrixil in AML, November 2026: https://www.vivesto.com/en/vivesto-receives-orphan-drug-designation-in-the-u-s-for-cantrixil-in-aml/
- FDA orphan designation, acute myeloid leukaemia, 1 November 2026: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1170226

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Cantrixil](https://onco.cc/drugs/cantrixil/)

---
JSON: https://onco.cc/api/v1/entities/vivesto.json